Loading…
Loading…
EWTX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for EWTX and 80,000+ other tickers.
See exactly how EWTX's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EWTX and 80,000+ other tickers.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% – – EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 – BOULDER, Colo., Oct. 8, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, today announced the dosing of the first patient in EQUINOX-HFpEF, a Phase 2 clinical trial evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction (HFpEF) who have a left ventricular ejection fraction (LVEF) of at least 50%.
BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on September 30, 2026, Edgewise granted inducement stock options to purchase a total of 7,500 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 3,751 shares of Edgewise's common stock to 3 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve - - Company to host webcast to discuss these findings today at 8:30 a.m. Eastern Time - BOULDER, Colo.
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.